The most useful tissue-based biomarkers in breast cancer include estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor receptor 2 (Her-2), and ki67 are used to detect prognosis and guiding systemic therapy. This evidence concerns the gene ERBB2 and breast carcinoma.